Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy
Rhea-AI Summary
Silo Pharma (Nasdaq: SILO) announced the European Patent Office issued a Rule 71(3) communication indicating intent to grant a patent (European Application No. 20786878.7) covering prophylactic use of 5-HT4 receptor agonists to prevent stress-induced fear and depressive-like behavior.
The allowance expands Silo's licensed IP from Columbia University, may protect major European markets once granted, and the company is evaluating Unitary Patent and national validations to maximize coverage.
Positive
- EPO intent to grant for European application No. 20786878.7
- Allowed claims cover preventative use targeting the 5-HT4 pathway
- Company is evaluating Unitary Patent and national validations to broaden coverage
Negative
- Allowance is a Rule 71(3) communication; patent not yet formally granted
- European protection subject to national validations and Unitary Patent decisions
- Silo's rights are licensed from Columbia University, implying dependence on licensed IP
News Market Reaction – SILO
In the Apr 7 session, SILO gained 49.02%, reflecting a significant positive market reaction. Argus tracked a peak move of +120.7% during that session. Our momentum scanner triggered 40 alerts that day, indicating elevated trading interest and price volatility. Trading volume was exceptionally heavy at 30.2x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 23 | Share buyback launch | Positive | +24.0% | Board-authorized repurchase program of up to $1,000,000 in stock. |
| Feb 18 | Japan patent allowance | Positive | -3.2% | Notice of Allowance in Japan for SPC-15 PTSD intranasal patent. |
| Dec 30 | Phase 1 LOI SPC-15 | Positive | +4.7% | LOI with Allucent to support two planned Phase 1 SPC-15 studies. |
| Nov 17 | Allucent IND support | Positive | -1.1% | Partnership with Allucent to prepare 2026 FDA IND for SPC-15. |
| Oct 29 | Crypto treasury move | Neutral | -1.9% | Selection of Alphaledger T12 tokenized RWA fund for treasury strategy. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news shows mixed reactions: buyback and clinical steps often saw positive moves, while some IP and strategic news drew modest pullbacks.
Over the last six months, Silo reported a mix of IP, clinical, capital markets, and crypto‑strategy developments. A $1,000,000 buyback authorization on Feb 23, 2026 coincided with a +24% move, while a Japanese PTSD patent allowance on Feb 18, 2026 saw a -3.17% reaction. Earlier, Allucent collaborations for SPC-15 clinical planning and an IND strategy generated modestly positive or slightly negative moves. A tokenized RWA crypto-treasury step in Oct 2025 drew a small decline. Today’s European patent allowance further extends the IP expansion trend.
Key Terms
european patent office regulatory
serotonin 4 receptor agonists medical
5-ht4 medical
unitary patent regulatory
cns therapeutics medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
EPO Greenlights Claims Covering Preventative use of therapy targeting 5-HT4 Pathway and Expands Silo Pharma IP Portfolio
SARASOTA, FL, April 06, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that the European Patent Office (EPO) has issued a Rule 71(3) communication indicating its intent to grant a patent for an European patent application titled “Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress” (European Patent Application No. 20786878.7) that the Company has an exclusive license from Columbia University.
The allowed claims cover methods of preventing stress-induced fear and depressive-like behavior and associated affective disorders using selected serotonin 4 (5-HT4) receptor agonists — a differentiated approach targeting pathways associated with stress resilience rather than just symptom management.
“This is a high-value milestone that strengthens our global intellectual property position and underscores the potential of our 5-HT4 program,” said Eric Weisblum, CEO of Silo Pharma. “We believe this approach represents a compelling shift toward proactive treatment of stress-related disorders, which remain a massive and underserved market.”
The patent, once granted, is expected to protect major European markets, further enhancing Silo’s strategic positioning as it advances its pipeline. The Company is evaluating Unitary Patent protection and key national validations to maximize geographic coverage and long-term value.
With growing global focus on mental health and stress-related conditions, Silo Pharma continues to build a portfolio targeting next-generation CNS therapeutics with differentiated mechanisms of action.
About Silo Pharma, Inc.
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease. Silo’s research is conducted in collaboration with leading universities and laboratories. silopharma.com
Forward Looking Statements
This news release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including statements about the intended use of proceeds from the offering, changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.
Contact
(800) 705-0120
investors@silopharma.com
